Background {#Sec1}
==========

Atrial fibrillation is the most common arrhythmia of the heart with a prevalence of approximately 2% in the western world \[[@CR1], [@CR2]\]. Atrial flutter, another arrhythmia, occurs less often with an incidence of approximately 200,000 new patients per year in the USA \[[@CR3]\]. The prevalence of both atrial fibrillation and atrial flutter are increasing possibly because of a greater life expectancy in the general population, an increased prevalence of risk factors for atrial fibrillation and atrial flutter, and an improved ability to suspect and diagnose the arrhythmias \[[@CR1], [@CR4], [@CR5]\]. Atrial fibrillation and atrial flutter are associated with an increased risk of death and morbidities \[[@CR6]--[@CR12]\]. The risks of both cerebral stroke and heart failure are increased nearly fivefold in patients with atrial fibrillation and atrial flutter, and an estimated 20% of every stroke may be due to atrial fibrillation \[[@CR6]--[@CR11]\]. Atrial fibrillation and atrial flutter also have a significant impact on healthcare costs and account for approximately 1% of the National Health Service budget in the UK and approximately 26 billion dollars of annual expenses in the USA \[[@CR13], [@CR14]\].

Definition and classification {#Sec2}
-----------------------------

The atriums of the heart receive blood returning from the body and pump it further ahead to the ventricles. Atrial fibrillation and atrial flutter are defined as abnormal heart rhythms that arise from improper electrical activity of the heart which lead to ineffective mechanical contraction \[[@CR15]--[@CR17]\]. The ineffective mechanical contraction stresses the muscle cells of the heart which over time may cause heart failure \[[@CR18], [@CR19]\]. Persistent rapid rates can also cause or worsen a tachycardia-mediated cardiomyopathy \[[@CR20]\].

Atrial fibrillation and atrial flutter can be asymptomatic or lead to symptoms such as palpitations, dyspnoea, and dizziness \[[@CR21]\]. Atrial fibrillation may be diagnosed using an electrocardiogram as (1) irregular R-R intervals (when atrioventricular conduction is present), (2) absence of distinct repeating *P*-waves, and/or (3) irregular atrial activity \[[@CR16], [@CR17]\]. Atrial flutter may be diagnosed using an electrocardiogram as characteristic flutter waves (*F*-waves) at a regular atrial rate of 250 to 350 beats per minute. The flutter waves may resemble *P*-waves or have a 'saw-tooth' shape \[[@CR22]\].

Atrial fibrillation may either be non-valvular or valvular, where the latter form is characterised by rheumatic mitral stenosis, mechanical heart valve, tissue heart valve, or mitral valve repair \[[@CR1]\]. However, the definition of the terms non-valvular and valvular lacks consistency in both trials and guidelines \[[@CR23], [@CR24]\]. A paper has proposed a new term 'mechanical and rheumatic mitral valvular atrial fibrillation', as they report that only mechanical valves and mitral stenosis have special needs in regard to antithrombotic treatment \[[@CR24]\].

The development of atrial fibrillation is associated with various risk factors, e.g. ageing, obesity, smoking, hypertension, diabetes, and other cardiac diseases (valvular or other structural heart diseases) \[[@CR17], [@CR25]\]. The development of atrial flutter is presumably associated with prolonged PR interval and some of the same risk factors as atrial fibrillation \[[@CR8]\]. However, it has not been demonstrated that atrial flutter is associated with either obesity, diabetes, hypertension, or valvular heart disease \[[@CR8]\]. Both atrial fibrillation and atrial flutter may also occur in patients with no risk factors (so called lone atrial fibrillation or lone atrial flutter) \[[@CR3]\].

Based on the duration of the arrhythmia, atrial fibrillation may be divided into five different forms \[[@CR15]--[@CR17]\]:Recent-onset atrial fibrillationParoxysmal atrial fibrillationPersistent atrial fibrillationLong-standing persistent atrial fibrillationPermanent atrial fibrillation

Based on the re-entrant circuit, atrial flutter may be divided into two different forms:Typical atrial flutter is a macro-reentrant atrial tachycardia that can be subdivided based on the rotation of the circuit to counterclockwise atrial flutter (90% of patients) or clockwise atrial flutter (10% of patients) \[[@CR26]\].Atypical atrial flutter is defined as any atrial tachycardia with an ECG pattern of continuous undulation of the atrial complex, different from typical atrial flutter, at a rate of ≥240 beats per minute \[[@CR26]\].

Pathophysiology {#Sec3}
---------------

The pathogenesis of atrial fibrillation is thought to be an interaction between a trigger for initiation and an abnormal tissue substrate for maintenance \[[@CR25]\].

The trigger for initiation is often a rapidly firing focus most often located in the left atrium and the proximal parts of the pulmonary veins \[[@CR27]\]. The abnormal tissue substrate for maintenance is often a result of an underlying heart disease like coronary heart disease, valvular heart disease, cardiomyopathies, or heart failure \[[@CR16]\]. The pathogenesis of the abnormal tissue substrate is induced by inflammation \[[@CR28]\], fibrosis \[[@CR29]\], or hypertrophy \[[@CR30]\].

Electric remodelling, such as refractory period shortening, occurs after a period of continuous atrial fibrillation that further facilitate atrial fibrillation, i.e. atrial fibrillation leads to atrial fibrillation \[[@CR30], [@CR31]\]. Nevertheless, the electric remodelling is often reversible if sinus rhythm is restored, though it can become permanent if atrial fibrillation persists \[[@CR31]\].

Atrial flutter is classified as a macro-reentrant tachycardia. The macro-reentrant tachycardia occurs when an electrical impulse recurrently moves in a self-perpetuating circuit within the heart, rather than moving from one end of the heart to the other and terminating \[[@CR26]\].

Antithrombotic treatment {#Sec4}
------------------------

As mentioned in the '[Background](#Sec1){ref-type="sec"}' section, the risk of stroke is increased nearly fivefold in patients with atrial fibrillation and atrial flutter \[[@CR10]\]. Antithrombotic treatment is necessary to reduce the risk of stroke in high-risk patients with atrial fibrillation and atrial flutter, regardless of the management strategy \[[@CR16]\]. The risk of stroke in patients with atrial fibrillation and atrial flutter can be estimated by the CHA2DS2-VASc score \[[@CR32]\], while the risk of bleeding can be estimated by the HAS-BLED score \[[@CR33]\]. Combined, these may help the physician determine the patient's need for antithrombotic treatment \[[@CR16]\].

Antithrombotic drugs aim at reducing the formation of thrombi by affecting different clotting processes. Depending on the mechanism, the drugs are divided into either anticoagulants or antiplatelet drugs. The classification, mechanism, and examples of anticoagulants and antiplatelet drugs are summarised in Table [1](#Tab1){ref-type="table"}.Table 1The classification, mechanism, and examples of anticoagulants and antiplatelet drugsClassMechanismExamplesAnticoagulantsAffect the coagulation cascade to prevent blood coagulation \[[@CR112]\]Vitamin K-dependent antagonists\
•Warfarin\
Non-vitamin K-dependent antagonists\
•Dabigatran\
•Rivaroxaban\
•Apixaban\
•Edoxaban\
Heparin\
•Unfractionated heparin\
•Low-molecular-weight heparinAntiplatelet drugsTheoretically affect the migration and aggregation of platelets, consequently aiming at inhibiting thrombus formation \[[@CR112]\]•Aspirin\
•Clopidogrel\
•Prasugrel\
•Ticagrelor\
•Cangrelor\
•Abciximab\
•Eptifibatid\
•Dipyridamole

The comparative efficacy and safety between anticoagulants and antiplatelet drugs has been assessed. Two systematic reviews have shown that both warfarin and apixaban are superior to antiplatelet drugs for preventing stroke, with a similar rate of major bleeding and intracranial haemorrhage \[[@CR34], [@CR35]\].

The comparative efficacy and safety between warfarin and non-vitamin K-dependent antagonist has been assessed. Ruff et al. showed in a systematic review that the non-vitamin K-dependent antagonists compared with warfarin significantly reduced the risk of all-cause mortality by 10%, stroke by 19%, and intracranial haemorrhage by 52%. However, the risk of gastrointestinal bleeding was increased by 25% by the non-vitamin K-dependent antagonists \[[@CR36]\].

Description of the interventions {#Sec5}
================================

Two different overall intervention strategies may be used for atrial fibrillation and atrial flutter---a rhythm control strategy and a rate control strategy \[[@CR16]\]. The overall aims of a rhythm control strategy and a rate control strategy differ. A rhythm control strategy aims at obtaining and maintaining sinus rhythm, while a rate control strategy is an overall term for a strategy where the short- and long-term aim is to lower the ventricular frequency \[[@CR25]\]. Patients that receive rhythm control will often need some kind of rate control until they have obtained sinus rhythm.

The interventions used for both rhythm- and rate control strategies encompass both drugs and ablation. In addition, electrical cardioversion is also used for rhythm control.

The drugs used in both a rhythm control strategy and a rate control strategy are classified according to two different classifications: the Vaughan Williams classification and the Sicilian Gambit classification.The Vaughan Williams classification classifies the drugs in five different classes according to their general effect. Class I and III drugs are mainly used for a rhythm control strategy; class II and IV drugs are mainly used for a rate control strategy; and class V drugs are used for both strategies \[[@CR37]\]. The Vaughan Williams classification is summarised in Table [2](#Tab2){ref-type="table"}.Table 2The Vaughan Williams classificationClassMechanismExamplesIaNa^+^ channel block (moderate)•Quinidine\
•Ajmaline\
•Procainamide\
•DisopyramideIbNa^+^ channel block (weak)•Lidocaine\
•Phenytoin\
•Mexiletine\
•TocainideIcNa^+^ channel block (strong)•Flecainide\
•Propafenone\
•Encainide\
•MoricizineIIBeta-blocker•Propranolol\
•Carvedilol\
•Esmolol\
•Timolol\
•Metoprolol\
•Atenolol\
•Bisoprolol\
•NebivololIIIK^+^ channel blocker•Amiodarone\
•Dronedarone\
•Sotalol\
•Ibutilide\
•Dofetilide\
•VernakalantIVCa^2+^ channel blocker•Verapamil\
•DiltiazemVVariable•Adenosine\
•Digoxin\
•Magnesium sulphateThe Sicilian Gambit classification places a greater approach on the underlying mechanism of the drugs and classifies each drug according to the effects on bio-cellular channels, receptors, and pumps. We will not describe this classification in detail but refer to the work by the European Society of Cardiology \[[@CR38]\].

We will in this systematic review use the Vaughan Williams classification which is the most commonly used classification.

Rhythm control strategies {#Sec6}
-------------------------

A rhythm control strategy typically uses medical rhythm control or electrical cardioversion as the main rhythm control intervention. If they do not work, catheter ablation or surgical ablation may be considered \[[@CR39]\].

Medical rhythm control {#Sec7}
----------------------

Medical rhythm control involves antiarrhythmic drugs and is used for either (1) cardioversion of atrial fibrillation or atrial flutter to sinus rhythm or (2) maintenance of sinus rhythm \[[@CR16]\].

The main drugs used for medical cardioversion of atrial fibrillation and atrial flutter are flecainide (class Ic), propafenone (class Ic), dofetilide (class III), and amiodarone (class III) \[[@CR16]\]. A systematic review showed that intravenous vernakalant (class III), intravenous propafenone (class Ic), and both oral and intravenous flecainide (class Ic) seemed to be significantly more effective than placebo at restoring sinus rhythm within 2 h of administration in recent-onset atrial fibrillation \[[@CR40]\]. When they analysed for successful cardioversion within 8--24 h, oral amiodarone (class III), oral flecainide (Ic), and both oral and intravenous propafenone (class Ic) seemed to be significantly more effective than placebo \[[@CR40]\].

The main drugs used for maintenance of sinus rhythm are amiodarone (class III), dofetilide (class III), dronedarone (class III), flecainide (class Ic), propafenone (class Ic), beta blockers (class II), and sotalol (class III) \[[@CR16]\]. Lafuente-Lafuente et al. showed in a Cochrane review that drugs belonging to class Ia (disopyramide and quinidine), class Ic (flecainide and propafenone), class II (metoprolol), and class III (amiodarone, dofetilide, dronedarone, and sotalol) were moderately effective in maintaining sinus rhythm compared with patients not receiving antiarrhythmic drugs (56). Nonetheless, all drugs were associated with adverse events, including proarrhythmia (new or more frequent occurrence of pre-existing arrhythmias) \[[@CR41]\]. Treatment with quinidine (class Ia), disopyramide (class Ia), or sotalol (class III) compared with not receiving antiarrhythmic drugs was associated with higher risks of all-cause mortality and serious adverse events \[[@CR41]\]. In regard to class Ic drugs (flecainide and propafenone), no increased risk of mortality was found. However, as the data obtained on mortality with flecainide (class Ic) and propafenone (class Ic) seemed sparse, the authors concluded that the result was uncertain \[[@CR41]\]. Guidelines recommend that flecainide (class Ic) and propafenone (class Ic) should only be used in patients without ischaemic heart disease or heart failure \[[@CR16], [@CR42]\]. This is based on a randomised trial from 1989, the Cardiac Arrhythmia Suppression Trial (CAST), that compared antiarrhythmic drug therapy with placebo in patients with asymptomatic or mildly symptomatic ventricular arrhythmia (six or more ventricular premature beats per hour) after myocardial infarction \[[@CR43]\]. The trial showed an increased risk of mortality and sudden cardiac death caused by ventricular arrhythmias in the patients receiving encainide (class Ic) and flecainide (class Ic) compared with placebo \[[@CR43]\].

In several systematic reviews, amiodarone (class III) was shown to be better than class I (flecainide, propafenone, disopyramide, and quinidine) and other class III drugs (sotalol, dofetilide, and dronedarone) at maintaining sinus rhythm \[[@CR41], [@CR44]--[@CR46]\]. However, in one systematic review, amiodarone (class III) was shown to induce a higher number of adverse events \[[@CR46]\].

Electrical cardioversion rhythm control {#Sec8}
---------------------------------------

Electrical cardioversion is a non-invasive procedure that uses electrical shock to convert atrial fibrillation and atrial flutter (or other arrhythmias) into sinus rhythm \[[@CR16]\]. Current evidence supports the use of electrical cardioversion with biphasic waveforms with an intensity of 200 J for atrial fibrillation, as the proportion of success is 91 to 94% \[[@CR47]--[@CR49]\]. The monophasic waveform requires intensity up to 360 J to work, and the proportion of success is 79 to 85% \[[@CR47]--[@CR49]\]. For atrial flutter, evidence supports the use of biphasic waveforms with an intensity of 50 to 100 J \[[@CR50], [@CR51]\]. It has been shown that longer duration of atrial fibrillation was inversely associated with cardioversion proportions \[[@CR52], [@CR53]\]. To enhance the effectiveness of the procedure, antiarrhythmic drugs, such as amiodarone (class III), flecainide (class Ic), ibutilide (class Ic), propafenone (class Ic), and sotalol (class III), can be used \[[@CR54]\].

Ablation procedures for rhythm control {#Sec9}
--------------------------------------

Two different ablation procedures may be used for rhythm control in patients with atrial fibrillation and atrial flutter---catheter ablation or surgical ablation. Both procedures do not involve controlling the heart rate but aim at obtaining sinus rhythm.

Catheter ablation may be indicated in patients with paroxysmal, persistent, or long-standing persistent atrial fibrillation or atrial flutter that is refractory or intolerant to medical rhythm control \[[@CR15]\]. Catheter ablation of atrial fibrillation is mostly performed in the left atrium, usually entering via the vena femoralis, vena jugularis interna, or vena subclavia. In the left atrium, a series of lesions are created, and the lesions are thought either to eliminate possible triggers originating from the pulmonary veins or to modify the substrate that maintains the atrial fibrillation \[[@CR15]\]. Catheter ablation may also be indicated in patients with typical atrial flutter where the lesions caused by catheter ablation are thought to interrupt the macro-reentrant circuit maintaining the atrial flutter \[[@CR55]\]. The main technique for either atrial fibrillation or atrial flutter is radiofrequency ablation that achieves myocardial necrosis through tissue heating \[[@CR15]\]. In an observational study, the risk of major complications (e.g. death, tamponade, total femoral pseudoaneurysm, or transient ischemic attack) after catheter ablation was found to be 4.5% based on 20,825 procedures \[[@CR56]\].

Surgical ablation is performed doing a Cox-Maze procedure by open-heart surgery or a less-invasive right mini thoracotomy \[[@CR57]\]. A Cox-Maze procedure is done by creating a number of surgical lesions in the left and right atrium in order to form scar tissue. The scar tissue inhibits the conduction of electricity, consequently disrupting the abnormal electrical impulses \[[@CR58]\]. The procedure is most often done concomitantly with other cardiac surgery than as a lone procedure \[[@CR57]\]. A randomised clinical trial compared surgical ablation with no surgical ablation during mitral-valve surgery and showed significantly higher conversion rates in the surgical ablation group \[[@CR59]\]. The risk of mortality was similar to both groups. However, there was a significantly higher rate of permanent pacemaker implantation in the surgical ablation group than in the no surgical ablation group \[[@CR59]\].

Rate control strategies {#Sec10}
-----------------------

### Medical rate control {#Sec11}

The drugs used for rate control in atrial fibrillation and atrial flutter are mainly beta blockers (class II), non-dihydropyridine calcium channel blockers (class IV), and digoxin (class V) \[[@CR16], [@CR22]\]. All three types of drugs work by lowering the heart rate which might consequently prevent excessive tachycardia and limit symptoms. Lowering the heart rate might theoretically prevent the development of heart failure and tachycardia-mediated cardiomyopathy \[[@CR18], [@CR20], [@CR60]\]. An observational study compared rate control with no rate control and showed lower risk of mortality in the patients receiving beta blockers (class II) or non-dihydropyridine calcium channel blockers (class IV). In contrast, the patients receiving digoxin (class V) seemed to have a higher risk of mortality \[[@CR61]\]. A systematic review compared rate control interventions with placebo and showed that selective beta blockers (class II), verapamil (class IV), diltiazem (class IV), and partial digoxin (class V) were better than placebo at lowering the heart rate \[[@CR62]\]. According to guidelines, beta blockers (class II) or non-dihydropyridine calcium channel blockers (class IV) are first-line therapy, while digoxin (class V) may be combined with one of them if they alone are insufficient to control the heart rate \[[@CR16]\]. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial showed that beta-blockers (class II) (with or without digoxin (class V)) achieved rate control (rest ≤80 beats/min) in 70% of the patients compared with 54% for non-dihydropyridine calcium channel blockers (class IV) (with or without digoxin (class V)) and 58% for digoxin (class V) (used without beta-blockers (class II) or non-dihydropyridine calcium channel blockers (class IV)) \[[@CR63]\]. Amiodarone (class III) may also control the heart rate, as it exhibits beta and calcium channel blockade in addition to its antiarrhythmic activity. However, amiodarone (class III) has extensive non-cardiac adverse events and is only used if other rate control drugs are not effective enough, not well tolerated, or contraindicated \[[@CR16]\]. According to guidelines, physicians should consider the patient's degree of symptoms, haemodynamic status, presence or absence of heart failure, and comorbidities when choosing which rate control intervention to use \[[@CR16]\].

During recent years, observational studies have compared digoxin versus no digoxin in patients with atrial fibrillation or atrial flutter and showed conflicting results \[[@CR64]--[@CR68]\]. Some studies have shown that digoxin seemed to increase the risk of all-cause mortality regardless of concomitant heart failure \[[@CR64], [@CR65]\], while others did not show any difference between the compared groups \[[@CR66]--[@CR68]\]. Nonetheless, guidelines recommend using digoxin as the primary drug for rate control in patients with atrial fibrillation or atrial flutter who have concomitant heart failure and reduced ejection fraction. Digoxin is also recommended for acute rate control in patients with preserved ejection fraction \[[@CR16], [@CR42], [@CR69]\].

### Ablation procedures for rate control {#Sec12}

Atrioventricular node ablation procedure is a rare but highly effective procedure that controls the ventricular heart rate with the help of a pacemaker \[[@CR70]\]. The procedure is done by ablation of the atrioventricular node via assess from vena femoralis dexter, consequently cancelling all electrical impulses from the atriums to the ventricles. Hence, the procedure induces complete atrioventricular block and permanent pacing is necessary \[[@CR71]\]. The procedure does not involve rhythm control, and atrial fibrillation or atrial flutter is still present after the procedure. The atrioventricular node ablation procedure primarily benefits patients with atrial fibrillation or atrial flutter who have symptoms refractory to medical rate control \[[@CR70]\].

Why is it important to do this review? {#Sec13}
======================================

Atrial fibrillation and atrial flutter are the most common arrhythmias of the heart and are associated with an increased risk of death and morbidities \[[@CR1]--[@CR3], [@CR6]--[@CR12]\]. The treatment of atrial fibrillation and atrial flutter is based on two overall treatment strategies---a rhythm control strategy and a rate control strategy \[[@CR16]\].

Several meta-analyses of randomised trials have compared rhythm control strategies with rate control strategies in patients with atrial fibrillation or atrial flutter \[[@CR72]--[@CR75]\]. Cordina et al. from 2005 included 2 trials with 4312 participants \[[@CR73]\]; Caldeira et al. from 2012 included 8 trials with 7499 participants \[[@CR75]\]; Chatterjee et al. from 2013 included 10 trials with 7867 participants \[[@CR74]\]; and Al-Khatib et al. from 2014 included 16 trials with 7608 participants \[[@CR72]\]. None of the reviews showed any difference in effects of any of the strategies on all-cause death and other patient-centred clinical outcomes. However, Chatterjee et al. showed lower risk of all-cause mortality in patients younger than 65 years in the rhythm control group compared with the rate control group \[[@CR74]\]. Cordina et al. showed significantly higher rates of adverse events in the rhythm control group compared with the rate control group \[[@CR73]\].

No former review comparing rhythm control strategies with rate control strategies has taken into account both risks of systematic errors and risks of random errors (Cochrane methodology, Trial Sequential Analysis, and the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) assessment) \[[@CR76]--[@CR79]\]. Therefore, it is still unclear whether a rhythm control strategy or a rate control strategy is the best treatment strategy in patients with atrial fibrillation and atrial flutter. In the present systematic review, we will collect and present current evidence of rhythm control versus rate control for atrial fibrillation and atrial flutter.

Objective {#Sec14}
=========

The objective of the study is to assess the beneficial and harmful effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter.

Methods {#Sec15}
=======

This systematic review protocol has been developed based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P) guidelines for reporting systematic reviews evaluating healthcare interventions \[[@CR80], [@CR81]\]. A PRISMA-P checklist file is attached (Additional file [1](#MOESM1){ref-type="media"}).

Criteria for considering studies for this review {#Sec16}
------------------------------------------------

### Types of studies {#Sec17}

Randomised clinical trials irrespective of trial design, setting, publication status, publication year, and language. We will not include quasi-randomised trials and observational studies for the assessments of harms. We are aware that this is a limitation of our review.

### Types of participants {#Sec18}

Patients with atrial fibrillation or atrial flutter. We will accept the definitions used by the trialists. Patients will be included irrespective of age, sex, and comorbidities.

### Types of interventions {#Sec19}

Rhythm control group: we will accept any type of rhythm control strategy, i.e. any intervention where the overall aim is to convert the atrial fibrillation or atrial flutter to sinus rhythm. Treatment elements of the rhythm control strategy could for example be flecainide, propafenone, dofetilide, amiodarone, dronedarone, sotalol, or electrical cardioversion (all irrespective of dose, rout of administration, and duration). We will accept if the rhythm control strategy also includes rate control interventions as part of treatment, but the overall aim (short or long term) has to be to obtain sinus rhythm.

Rate control group: we will accept any type of rate control strategy, i.e. any intervention where the overall aim is to control the heart rate and the focus is not to convert the atrial fibrillation or atrial flutter to sinus rhythm. Treatment elements of the rate control strategy could for example be beta blockers, non-dihydropyridine calcium channel blockers, digoxin, or amiodarone (all irrespective of dose, route of administration, and duration).

We will accept any type of co-intervention when such co-intervention is intended to be delivered similar to the rhythm control group and the rate control group.

### Types of outcome measures {#Sec20}

We will for all outcomes use the trial results reported at maximal follow-up. However, if the trialists report results at multiple time points, we will primarily use the results reported at the time point closest to 24 months.

#### Primary outcomes {#FPar1}

All-cause mortality.Serious adverse events. We will define a serious adverse event as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalisation or prolongation of existing hospitalisation, and resulted in persistent or significant disability or jeopardised the patient \[[@CR82]\].Quality of life measured on any valid scale.

#### Secondary outcomes {#FPar2}

Stroke (as defined by the trialists)Ejection fraction (continuous outcome)

All outcomes, except quality of life and ejection fraction, will be analysed as proportions of participants in each group.

Search methods for identification of studies {#Sec21}
--------------------------------------------

### Electronic searches {#Sec22}

We will search the Cochrane Central Register of Controlled Trials (CENTRAL), Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica database (EMBASE), Latin American and Caribbean Health Sciences Literature (LILACS), Science Citation Index Expanded on Web of Science, and BIOSIS in order to identify relevant trials. The preliminary search strategy for MEDLINE (Ovid) is given in Additional file [2](#MOESM2){ref-type="media"}.

We will search all databases from their inception to the present.

### Searching other resources {#Sec23}

The reference lists of relevant publications will be checked for any unidentified randomised trials. We will contact authors of included studies, and major pharmaceutical companies, by email asking for unpublished randomised trials. Further, we will search for ongoing trials on:ClinicalTrials.gov ([www.clinicaltrials.gov](http://www.clinicaltrials.gov/))Google Scholar (<https://scholar.google.dk/>)The Turning Research into Practice (TRIP) Database (<https://www.tripdatabase.com/>)European Medicines Agency (EMA) (<http://www.ema.europa.eu/ema/>)United States Food and Drug Administration (FDA) ([www.fda.gov](http://www.fda.gov/))China Food and Drug Administration (CFDA) (<http://eng.sfda.gov.cn/WS03/CL0755/>)Medicines and Healthcare products Regulatory Agency(<https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency>)The World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal (<http://apps.who.int/trialsearch/>)

Additionally, we will handsearch conference abstracts from cardiology conferences for relevant trials.

We will also consider relevant for the review unpublished and grey literature trials if we identify these.

Data collection and analysis {#Sec24}
============================

We will perform the review following the recommendations of the Cochrane Collaboration \[[@CR79]\]. The analyses will be performed using Review Manager 5 \[[@CR83]\] and Trial Sequential Analysis \[[@CR84]\]. In case of Review Manager statistical software not being sufficient, we will use STATA 14 \[[@CR85]\].

Selection of studies {#Sec25}
--------------------

Two authors (NJS and SS) will independently screen titles and abstracts. We will retrieve all relevant full-text study reports/publications, and two review authors (NJS and SS) will independently screen the full text and identify and record reasons for exclusion of the ineligible studies. We will resolve any disagreement through discussion or, if required, we will consult a third person (JCJ). Trial selection will be displayed in an adapted flow diagram as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@CR86]\].

Data extraction and management {#Sec26}
------------------------------

Four authors (NJS, SS, EEN, and JF) will in pairs extract data independently from included trials. Disagreements will be resolved by discussion with a fifth author (JCJ). We will assess duplicate publications and companion papers of a trial together to evaluate all available data simultaneously (maximise data extraction, correct bias assessment). We will contact the trial authors by email to specify any additional data, which may not have been reported sufficiently or at all in the publication.

### Trial characteristics {#Sec27}

Bias risk components (as defined below); trial design (parallel, factorial, or crossover); number of intervention arms; length of follow-up; estimation of sample size; inclusion and exclusion criteria.

### Participant characteristics and diagnosis {#Sec28}

Number of randomised participants; number of analysed participants; number of participants lost to follow-up/withdrawals/crossover; compliance with medication; age range (mean or median) and sex ratio; type of arrhythmia (atrial fibrillation or atrial flutter); baseline numbers of cardiovascular risk factors (i.e. diabetes mellitus, hypertension, hyperlipidaemia, or smoking); baseline number of participants with heart failure; baseline number of participants with valvular heart disease; baseline number of participants with previous myocardial infarction; baseline number of participants with previous revascularisation; and baseline number of participants with previous angina.

We will additionally report the proportion of participants in the compared groups who receive electrical cardioversion, atrioventricular node ablation, catheter ablation, and surgical ablation.

### Rhythm control strategy characteristics {#Sec29}

Type of rhythm control intervention, type of rate control intervention, dose of intervention, duration of therapy, and mode of administration.

### Rate control strategy characteristics {#Sec30}

Type of rate control intervention, dose of intervention, duration of therapy, and mode of administration.

### Co-intervention characteristics {#Sec31}

Type of co-intervention; dose of co-intervention; duration of co-intervention; and mode of administration.

### Outcomes {#Sec32}

All outcomes listed above will be extracted from each randomised clinical trial, and we will identify if outcomes are incomplete or selectively reported according to the criteria described later in 'incomplete outcome data' bias domain and 'selective outcome reporting' bias domain.

### Notes {#Sec33}

Funding of the trial and notable conflicts of interest of trial authors will be extracted, if available.

We will note in the 'Characteristics of included studies' table if outcome data were not reported in a usable way. Two review authors (NJS and SS) will independently transfer data into the Review Manager file \[[@CR83]\]. Disagreements will be resolved through discussion or, if required, we will consult with a third author (JCJ).

### Assessment of risk of bias in included studies {#Sec34}

We will use the instructions given in the Cochrane Handbook for Systematic Reviews of Interventions \[[@CR79]\] in our evaluation of the methodology and hence the risk of bias of the included trials. We will evaluate the methodology in respect of:Random sequence generationAllocation concealmentBlinding of participants and treatment providersBlinding of outcome assessmentIncomplete outcome dataSelective outcome reportingOther risks of biasOverall risk of bias

These components enable classification of randomised trials with low risk of bias and high risk of bias. The latter trials tend to overestimate positive intervention effects and underestimate negative effects \[[@CR87]--[@CR93]\].

We will classify the trials according to the following criteria.

### Random sequence generation {#Sec35}

Low risk: If sequence generation was achieved using computer random number generator or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were also considered adequate if performed by an independent adjudicator.Unclear risk: If the method of randomisation was not specified, but the trial was still presented as being randomised.High risk: If the allocation sequence is not randomised or only quasi-randomised. These trials will be excluded.

### Allocation concealment {#Sec36}

Low risk: If the allocation of patients was performed by a central independent unit, on-site locked computer, identical-looking numbered sealed envelopes, drug bottles, or containers prepared by an independent pharmacist or investigator.Uncertain risk: If the trial was classified as randomised but the allocation concealment process was not described.High risk: If the allocation sequence was familiar to the investigators who assigned participants.

### Blinding of participants and treatment providers {#Sec37}

Low risk: If the participants and the treatment providers were blinded to intervention allocation and this was described.Uncertain risk: If the procedure of blinding was insufficiently described.High risk: If blinding of participants and the treatment providers was not performed.

### Blinding of outcome assessment {#Sec38}

Low risk of bias: If it was mentioned that outcome assessors were blinded and this was described.Uncertain risk of bias: If it was not mentioned if the outcome assessors in the trial were blinded or the extent of blinding was insufficiently described.High risk of bias: If no blinding or incomplete blinding of outcome assessors was performed.

### Incomplete outcome data {#Sec39}

Low risk of bias: If missing data were unlikely to make treatment effects depart from plausible values. This could be either (1) there were no drop-outs or withdrawals for all outcomes or (2) the numbers and reasons for the withdrawals and drop-outs for all outcomes were clearly stated and could be described as being similar to both groups. Generally, the trial is judged as at a low risk of bias due to incomplete outcome data if drop-outs are less than 5%. However, the 5% cut-off is not definitive.Uncertain risk of bias: If there was insufficient information to assess whether missing data were likely to induce bias on the results.High risk of bias: If the results were likely to be biased due to missing data either because the pattern of drop-outs could be described as being different in the two intervention groups or the trial used improper methods in dealing with the missing data (e.g. last observation carried forward).

### Selective outcome reporting {#Sec40}

Low risk of bias: If a protocol was published before or at the time the trial was begun and the outcomes specified in the protocol were reported on. If there is no protocol or the protocol was published after the trial has begun, reporting of all-cause mortality and serious adverse events will grant the trial a grade of low risk of bias.Uncertain risk of bias: If no protocol was published and the outcome all-cause mortality and serious adverse events were not reported on.High risk of bias: If the outcomes in the protocol were not reported on.

### Other risks of bias {#Sec41}

Low risk of bias: If the trial appears to be free of other components (for example, academic bias or for-profit bias) that could put it at risk of bias.Unclear risk of bias: If the trial may or may not be free of other components that could put it at risk of bias.High risk of bias: If there are other factors in the trial that could put it at risk of bias (for example, authors conducted trials on the same topic, for-profit bias, etc.).

### Overall risk of bias {#Sec42}

Low risk of bias: The trial will be classified as overall 'low risk of bias' only if all of the bias domains described in the above paragraphs are classified as 'low risk of bias'.High risk of bias: The trial will be classified as 'high risk of bias' if any of the bias risk domains described in the above are classified as 'unclear' or 'high risk of bias'.

We will assess the domains 'blinding of outcome assessment', 'incomplete outcome data', and 'selective outcome reporting' for each outcome result. Thus, we can assess the bias risk for each outcome assessed in addition to each trial. Our primary conclusions will be based on the results of our primary outcome results with overall low risk of bias. Both our primary and secondary conclusions will be presented in the summary of findings tables.

### Differences between the protocol and the review {#Sec43}

We will conduct the review according to this published protocol and report any deviations from it in the '[Differences between the protocol and the review](#Sec43){ref-type="sec"}' section of the systematic review.

### Measures of treatment effect {#Sec44}

#### Dichotomous outcomes {#FPar3}

We will calculate risk ratios (RRs) with 95% confidence interval (CI) for dichotomous outcomes, as well as the Trial Sequential Analysis-adjusted CIs (see below).

#### Continuous outcomes {#FPar4}

We will calculate the mean differences (MDs) and the standardised mean difference (SMD) with 95% CI for continuous outcomes, as well as the Trial Sequential Analysis-adjusted CIs (see below).

### Dealing with missing data {#Sec45}

We will, as first option, contact all trial authors to obtain any relevant missing data (i.e. for data extraction and for assessment of risk of bias, as specified above).

#### Dichotomous outcomes {#FPar5}

We will not impute missing values for any outcomes in our primary analysis. In two of our sensitivity analyses (see paragraph below), we will impute data.

#### Continuous outcomes {#FPar6}

We will primarily analyse scores assessed at single time points. If only changes from baseline scores are reported, we will analyse the results together with follow-up scores \[[@CR79]\]. If standard deviations (SDs) are not reported, we will calculate the SDs using trial data, if possible. We will not use intention-to-treat data if the original report did not contain such data. We will not impute missing values for any outcomes in our primary analysis. In our sensitivity analysis (see paragraph below) for continuous outcomes, we will impute data.

### Assessment of heterogeneity {#Sec46}

We will primarily investigate forest plots to visually assess any sign of heterogeneity. We will secondly assess the presence of statistical heterogeneity by chi^2^ test (threshold *P* \< 0.10) and measure the quantities of heterogeneity by the *I* ^2^ statistic \[[@CR94], [@CR95]\].

We will follow the recommendations for threshold by the *Cochrane Handbook for Systematic Reviews of Interventions* \[[@CR79]\]:0 to 40%: might not be important30 to 60%: may represent moderate heterogeneity50 to 90%: may represent substantial heterogeneity75 to 100%: may represent considerable heterogeneity

We will investigate possible heterogeneity through subgroup analyses. Ultimately, we may decide that a meta-analysis should be avoided \[[@CR79]\].

### Assessment of reporting biases {#Sec47}

We will use a funnel plot to assess reporting bias if ten or more trials are included. We will visually inspect funnel plots to assess the risk of bias. We are aware of the limitations of a funnel plot (i.e. a funnel plot assesses bias due to small sample size). From this information, we assess possible reporting bias. For dichotomous outcomes, we will test asymmetry with the Harbord test \[[@CR96]\] if *τ* ^2^ is less than 0.1 and with the Rücker test if *τ* ^2^ is more than 0.1. For continuous outcomes, we will use the regression asymmetry test \[[@CR97]\] and the adjusted rank correlation \[[@CR98]\].

#### Unit of analysis issues {#FPar7}

We will only include randomised clinical trials. For trials using crossover design, only data from the first period will be included \[[@CR79], [@CR99]\]. There will therefore not be any unit of analysis issues. We will not include cluster randomised trials.

### Data synthesis {#Sec48}

#### Meta-analysis {#FPar8}

We will undertake this meta-analysis according to the recommendations stated in the *Cochrane Handbook for Systematic Reviews of Interventions* \[[@CR79]\], Keus et al. \[[@CR78]\], and the eight-step assessment suggested by Jakobsen et al. \[[@CR76]\]. We will use the statistical software Review Manager 5.3 \[[@CR83]\] provided by Cochrane to analyse data.

We will assess our intervention effects with both random-effects meta-analyses \[[@CR100]\] and fixed-effects meta-analyses \[[@CR101]\]. We will use the more conservative point estimate of the two \[[@CR76]\]. The more conservative point estimate is the estimate closest to zero effect. If the two estimates are similar, we will use the estimate with the widest CI. We use three primary outcomes, and therefore, we will consider a *P* value of 0.025 or less as the threshold for statistical significance \[[@CR76]\]. We use two secondary outcomes, and therefore, we will consider a *P* value of 0.033 or less as threshold for statistical significance \[[@CR76], [@CR102]\]. We will investigate possible heterogeneity through subgroup analyses. Ultimately, we may decide that a meta-analysis should be avoided \[[@CR79]\]. We will use the eight-step procedure to assess if the thresholds for significance are crossed \[[@CR76]\]. Our primary conclusion will be based on results with low risk of bias \[[@CR76]\].

Where multiple trial arms are reported in a single trial, we will include only the relevant arms. If two comparisons are combined in the same meta-analysis, we will halve the control group to avoid double-counting \[[@CR79]\].

Trials with a factorial design will be included. In case of, e.g. a 2 × 2 factorial designed trial, the two groups receiving rhythm control interventions will be considered rhythm control groups, while the two groups receiving rate control interventions will be considered rate control groups.

If quantitative synthesis is not appropriate, we will report the results in a narrative way.

#### Trial Sequential Analysis {#FPar9}

Traditional meta-analysis runs the risk of random errors due to sparse data and repetitive testing of accumulating data when updating reviews. We wish to control the risks of type I errors and type II errors. We will therefore perform Trial Sequential Analysis on the outcomes, in order to calculate the required information size (that is the number of participants needed in a meta-analysis to detect or reject a certain intervention effect) and the cumulative Z-curve's breach of relevant trial sequential monitoring boundaries \[[@CR77], [@CR84], [@CR103]--[@CR110]\]. A more detailed description of Trial Sequential Analysis can be found in the Trial Sequential Analysis manual \[[@CR108]\] and at <http://www.ctu.dk/tsa/>.

For dichotomous outcomes, we will estimate the required information size based on the observed proportion of patients with an outcome in the control group (the cumulative proportion of patients with an event in the control groups relative to all patients in the control groups), a relative risk reduction of 15%, an alpha of 2.5% for our primary outcomes and an alpha of 3.3% for our secondary outcomes, a beta of 10%, and diversity as suggested by the trials in the meta-analysis. For continuous outcomes, we will in the Trial Sequential Analysis use the observed SD, a mean difference of the observed SD/2, an alpha of 2.5% for our primary outcomes and an alpha of 3.3% for our secondary outcomes, and a beta of 10%.

### Subgroup analysis and investigation of heterogeneity {#Sec49}

#### Subgroup analysis {#FPar10}

We will perform the following subgroup analysis when analysing the primary outcomes (all-cause mortality, serious adverse event, and quality of life).High risk of bias trials compared to low risk of bias trialsComparison of individual rhythm control interventions with any rate control interventionComparison of individual rate control interventions with any rhythm control interventionParticipants with atrial fibrillation compared to participants with atrial flutterAge of participants: 0 to 59 years, 60 to 79 years, and above 80 yearsDuration of atrial fibrillation: recent-onset atrial fibrillation (as defined by the trialists), paroxysmal atrial fibrillation (less than 7 days of onset), persistent atrial fibrillation (more than 7 days and less than 1 year of onset), and long-standing persistent atrial fibrillation (more than 1 year of onset)Duration of anticoagulation therapy: anticoagulation therapy until sinus rhythm for at least 4 weeks, anticoagulation therapy until sinus rhythm for at least 12 weeks, or anticoagulation therapy until end of follow-upMen compared to women

We will use the formal test for subgroup interactions in Review Manager \[[@CR83]\].

#### Sensitivity analysis {#FPar11}

To assess the potential impact of the missing data for dichotomous outcomes, we will perform the two following sensitivity analyses on both the primary and secondary outcomes.'Best-worst-case' scenario: We will assume that all participants lost to follow-up in the rhythm control group have survived, had no serious adverse event, and had no stroke and that all those participants lost to follow-up in the rate control group have not survived, had a serious adverse event, and had a stroke.'Worst-best-case' scenario: We will assume that all participants lost to follow-up in the rhythm control group have not survived, had a serious adverse event, and had a stroke and that all those participants lost to follow-up in the rate control group have survived, had no serious adverse event, and had no stroke.

We will present results of both scenarios in our review.

When analysing quality of life or ejection fraction, a 'beneficial outcome' will be the group mean plus two standard deviations (SDs) (we will secondly use one SD in another sensitivity analysis) of the group mean and a 'harmful outcome' will be the group mean minus two SDs (we will secondly use one SD in another sensitivity analysis) of the group mean \[[@CR76]\].

To assess the potential impact of missing SDs for continuous outcomes, we will perform the following sensitivity analysis.Where SDs are missing and it is not possible to calculate them, we will impute SDs from trials with similar populations and low risk of bias. If we find no such trials, we will impute SDs from trials with a similar population. As the final option, we will impute SDs from all trials.

We will present results of this scenario in our review.

Other post hoc sensitivity analyses might be warranted if unexpected clinical or statistical heterogeneity is identified during the analysis of the review results \[[@CR76]\].

#### 'Summary of Findings' table {#FPar12}

We will create a Summary of Findings table using each of the prespecified outcomes (all-cause mortality, serious adverse event, quality of life, stroke, and ejection fraction). We will use the five GRADE considerations (bias risk of the trials, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies which contribute data to the meta-analyses for the prespecified outcomes \[[@CR76], [@CR111]--[@CR113]\]. We will use methods and recommendations described in Chapter 8 (Section 8.5) and Chapter 12 of the *Cochrane Handbook for Systematic Reviews of Interventions* \[[@CR79]\] using GRADEpro software. We will justify all decisions to downgrade the quality of studies using footnotes, and we will make comments to aid the reader's understanding of the review where necessary. Firstly, we will present our results in the Summary of Findings table based on the results from the trials with low risk of bias, and secondly, we will present the results based on all trials.

Discussion {#Sec50}
==========

This protocol aims at comparing the effects of rhythm control strategies with the effects of rate control strategies in patients with atrial fibrillation and atrial flutter to determine the best overall treatment strategy. The outcomes will be all-cause mortality, serious adverse events, quality of life, stroke, and ejection fraction.

This protocol has a number of strengths. The predefined methodology is based on the *Cochrane Handbook for Systematic Reviews of Interventions* \[[@CR79]\], the eight-step assessment suggested by Jakobsen et al. \[[@CR76]\], Trial Sequential Analysis \[[@CR84]\], and GRADE assessment \[[@CR111]--[@CR113]\]. Hence, this protocol takes into account both risks of random errors and risks of systematic errors. Another strength of this protocol is that we pragmatically compare two overall treatment strategies with each other, i.e. the results of this review will potentially reflect the effects of the two strategies in clinical everyday practice.

Our protocol also has a number of limitations. The primary limitation is that both of the strategies we compare consist of multiple treatment elements and it is likely that different interventions have different effects. Hence, if we show a difference between the compared strategies, it will be difficult to conclude what exactly caused the difference in effect. To minimise this limitation, a number of subgroups are planned, but results of subgroup analyses should always be interpreted with great caution. Another limitation is the large number of comparisons which increase the risk of type 1 error. We have adjusted our thresholds for significance according to the number of primary outcomes, but, as mentioned, we have also included multiple subgroup analyses. This large risk of type 1 error will be taken into account when interpreting the review results.

Additional files {#Sec51}
================
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AFFIRM

:   The Atrial Fibrillation Follow-up Investigation of Rhythm Management

CAST

:   Cardiac Arrhythmia Suppression Trial

CENTRAL

:   The Cochrane Central Register of Controlled Trials

CFDA

:   China Food and Drug Administration

CI

:   Confidence interval

ECG

:   Electrocardiogram

EMA

:   European Medicines Agency

EMBASE

:   Excerpta Medica database

GRADE

:   The Grades of Recommendation, Assessment, Development, and Evaluation

LILACS

:   Latin American and Caribbean Health Sciences Literature

MD

:   Mean difference

MEDLINE

:   Medical Literature Analysis and Retrieval System Online

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

PRISMA-P

:   Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols

PROSPERO

:   International Prospective Register of Systematic Reviews

RR

:   Risk ratio

SMD

:   Standardised mean difference

TRIP

:   Turning Research Into Practice

WHO

:   World Health Organization
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We thank the *Systematic Reviews* for providing us with the PRISMA-P checklist to optimise the protocol. The PRISMA-P checklist is given in Additional file [1](#MOESM1){ref-type="media"}.
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